What do systematic reviews say?

Maintenance chemotherapy vs observation

Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.07 [0.91, 1.25]
  4 studies · 541 participants
  Moderate
• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.06 [0.97, 1.17]
  3 studies · 761 participants
  Moderate
• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 0.96 [0.65, 1.41]
  2 studies · 219 participants
  Moderate

Maintenance chemotherapy vs maintenance radiotherapy

Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.07 [0.75, 1.54]
  1 study · 141 participants
  Low
• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 0.86 [0.55, 1.37]
  1 study · 141 participants
  Low
• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 0.89 [0.51, 1.55]
  1 study · 141 participants
  Low

Maintenance chemotherapy vs maintenance radiotherapy

Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.06 [0.85, 1.32]
  1 study · 141 participants
  Low

Maintenance chemotherapy vs maintenance radiotherapy

Maintenance chemotherapy showed no clear difference in 5‐year OS compared with maintenance radiotherapy (low certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 0.97 [0.7, 1.35]
  1 study · 141 participants
  Low

Maintenance chemotherapy vs maintenance radiotherapy

Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 0.94 [0.58, 1.52]
  1 study · 141 participants
  Low

Maintenance chemotherapy vs observation

Maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1 [0.92, 1.08]
  5 studies · 679 participants
  Moderate

Maintenance chemotherapy vs observation

Maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.03 [0.96, 1.1]
  4 studies · 899 participants
  Moderate

Maintenance chemotherapy vs observation

Maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.08 [0.78, 1.49]
  2 studies · 219 participants
  Moderate

Platin‐based maintenance chemotherapy vs observation

Platin‐based maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.06 [0.94, 1.18]
  3 studies · 341 participants
  Moderate

Platin‐based maintenance chemotherapy vs observation

Platin‐based maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.07 [0.88, 1.31]
  2 studies · 219 participants
  Moderate

Platin‐based maintenance chemotherapy vs observation

Platin‐based maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.08 [0.78, 1.49]
  2 studies · 219 participants
  Moderate

Platin‐based maintenance chemotherapy vs observation

Platin‐based maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).

• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.04 [0.86, 1.24]
  3 studies · 341 participants
  Moderate
• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 1.18 [0.88, 1.58]
  2 studies · 219 participants
  Moderate
• Maintenance chemotherapy for ovarian cancer 2013 · Cochrane Headline outcomes only
  RR 0.96 [0.65, 1.41]
  2 studies · 219 participants
  Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  RR 1.31 [1.11, 1.55]
  1 study · 188 participants
  Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance may leads to higher hypertension grade ≥ 3 compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  RR 6.49 [2.02, 20.87]
  1 study · 1352 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.86 [0.67, 1.11]
  1 study · 282 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.56 [0.44, 0.72]
  1 study · 282 participants
  Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 146 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found